Drug news

Bayer HealthCare plans to file regorafenib at the FDA for Metastatic Colorectal Cancer in 2012

Read time: 1 mins

Last updated:18th Jan 2012

Published:18th Jan 2012

Source: Pharmawand

The 760 patient CORRECT trial of the oral multikinase inhibitor, regorafenib, from Bayer Healthcare was halted for the treatment of Metastatic Colorectal Cancer after showing an improvement of overall survival of 29% and placebo patients were transferred to regorafenib therapy. Bayer now reports that patients on regorafenib therapy lived 6.4 months longer compared with 5 months for those on placebo. Bayer plans to submit regorafenib for FDA approval for Metastatic Colorectal Cancer in 2012. Bayer has settled its dispute with Onyx Pharma which recognises regorafenib as a Bayer drug subject to receipt of a royalty on sales.

Learning Zone Homepage

Supportive care in oncology Learning Zone

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

The FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia below-the-knee

Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)

2 mins

Drug news

Promising findings in phase IIb/III clinical trial of NRX 101 vs. lurasidone for treatment of suicidal bipolar depression

NRx Pharmaceuticals, Inc. announced that its Breakthrough Therapy designated investigational drug NRX 101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduction in symptoms of akathisia – a side effect of antidepressants that is closely linked to suicide and considered a medical emergency

1 min

Drug news

FDA approval of Ingrezza Sprinkle (valbenazine) capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease

Neurocrine Biosciences, Inc. announced the FDA has approved Ingrezza Sprinkle (valbenazine) capsules, a new oral granules formulation of Ingrezza (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease

1 min

See all news